Cargando…
MEF2B is the ideal immunohistochemical marker to highlight neoplastic LP cells in nodular lymphocyte‐predominant Hodgkin lymphoma
Autores principales: | Torabi, Alireza, Fromm, Jonathan R, Naresh, Kikkeri N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188466/ https://www.ncbi.nlm.nih.gov/pubmed/37206275 http://dx.doi.org/10.1002/jha2.690 |
Ejemplares similares
-
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells
por: Seliem, Rania M., et al.
Publicado: (2011) -
Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016
por: Posthuma, Hidde L. A., et al.
Publicado: (2019) -
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Thyroid
por: Tavares Bello, Carlos, et al.
Publicado: (2016) -
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum
por: Rangan, Aruna, et al.
Publicado: (2017) -
Proposal of ‘reactive‐lymphocyte/histiocyte rich large B‐cell lymphoma’ as an alternate term for ‘nodular lymphocyte predominant Hodgkin lymphoma’ that would also address its overlap with T‐cell/histiocyte rich large B‐cell lymphoma
por: Naresh, Kikkeri N.
Publicado: (2022)